Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA will bring space station crew home early after medical issue08.01.2026 - 2Pat Finn, actor from 'The Middle,' dies at 60 after bladder cancer diagnosis24.12.2025
- 3US FDA unveils new pathway to approve personalized therapies12.11.2025
- 4Tech for Learning: Online Courses and Instructive Apparatuses01.01.1
- 5'Dancing with the Stars' semifinals: How to watch Episode 10 tonight, where to stream, who's left and more18.11.2025
- Esteem Stuffed Gaming Workstations to Consider
- Auschwitz Committee wants German auction of Holocaust items scrapped
- As world leaders enter climate talks, people in poverty have the most at stake
- The most effective method to Pick the Best Material Organization: Insider Tips
- Discovery of massive spider's web in Greece reveals unexpected behavior
- Savvy Watches: Which One Is Appropriate for You?
- Defeating An inability to embrace success in Scholarly world: Individual Victories
- Family Holiday spots
- Investigation reveals sperm donor passed on cancer risk to dozens of children across Europe
